Reasons to Add AngioDynamics Stock to Your Portfolio for Now

Key Takeaways ANGO posted strong fiscal Q2 2026 results, with revenue up 8.8% year over year to $79.4 million.ANGO's NanoKnife revenue rose 22.2% as prostate cancer procedures hit record volumes.ANGO's Auryon franchise grew 18.6%, supporting a Med Tech mix shift and gross margin expansion.AngioDynamics (ANGO) has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid second-quarter fiscal 2026 performance, positive ongoing studie ...